ALXN:NGS-Alexion Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 119.01

Change

-0.36 (-0.30)%

Market Cap

USD 26.48B

Volume

0.81M

Yahoo Analyst Target

USD 159.15 (33.73%)

STA Analyst Target

USD 158.24 (32.96%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-05-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

+1.89 (+1.07%)

USD 118.02B
GILD Gilead Sciences Inc.

+0.20 (+0.30%)

USD 88.20B
BIIB Biogen Inc.

+2.02 (+0.73%)

USD 59.02B
CELG Celgene Corporation

+1.92 (+2.57%)

USD 55.53B
SHPG Shire plc

+0.94 (+0.56%)

USD 51.75B
VRTX Vertex Pharmaceuticals Incorpo..

+0.06 (+0.04%)

USD 39.82B
REGN Regeneron Pharmaceuticals Inc.

-1.92 (-0.65%)

USD 31.78B
BMRN BioMarin Pharmaceutical Inc.

-1.75 (-1.96%)

USD 15.48B
GRFS Grifols S.A.

-0.03 (-0.13%)

USD 15.39B
INCY Incyte Corporation

-0.23 (-0.34%)

USD 14.11B

ETFs Containing ALXN

BBH VanEck Vectors Biotech ET.. 4.81 % 0.35 %

+0.43 (+0.37%)

USD 0.42B
FMDG Fieldstone Merlin Dynamic.. 4.37 % 0.00 %

+0.20 (+0.66%)

N/A
FBT First Trust Amex Biotech .. 3.71 % 0.56 %

+0.35 (+0.26%)

USD 1.51B
IBB iShares Nasdaq Biotechnol.. 3.67 % 0.47 %

+0.34 (+0.32%)

USD 8.80B
LALT PowerShares Multi-Strateg.. 1.32 % 0.87 %

-0.01 (-0.05%)

USD 4.42M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.48% 50% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.48% 49% F 41% F
Trailing 12 Months  
Capital Gain 3.11% 48% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.11% 47% F 39% F
Trailing 5 Years  
Capital Gain 18.34% 50% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.34% 50% F 35% F
Average Annual (5 Year Horizon)  
Capital Gain 2.82% 47% F 40% F
Dividend Return 2.82% 46% F 34% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.21% 82% B- 47% F
Risk Adjusted Return 10.00% 48% F 31% F
Market Capitalization 26.24B 98% A+ 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 71.80 2% F 9% F
Price/Book Ratio 2.98 60% D- 38% F
Price / Cash Flow Ratio 5.91 5% F 18% F
Price/Free Cash Flow Ratio 35.00 3% F 14% F
Management Effectiveness  
Return on Equity 5.83% 82% B- 56% F
Return on Invested Capital 7.53% 87% B+ 64% D
Return on Assets 3.83% 90% A- 74% C
Debt to Equity Ratio 35.25% 38% F 56% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

ALXN:NGS-Alexion Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 119.01

Change

-0.36 (-0.30)%

Market Cap

USD 26.48B

Volume

0.81M

Yahoo Analyst Target

USD 159.15 (33.73%)

STA Analyst Target

USD 158.24 (32.96%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-05-22